Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 21 Mar 2022
Genomics Australia to guide the future of genomic health and medicine over the coming decade
21 March 2022 - Through our 10 year Medical Research Future Fund (MRFF) plan, the Morrison Government is committed to ...
Posted by Michael Wonder on 21 Mar 2022
EMA publishes agenda for 21-24 March CHMP meeting
21 March 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 21 Mar 2022
ATAGI update following weekly COVID-19 meeting (16 March 2022)
21 March 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 16 ...
Posted by Michael Wonder on 21 Mar 2022
DoH publishes revised agenda for this month's PBAC meeting
21 March 2022 - This is the first time we can recall that the DoH has published a revised agenda ...
Posted by Michael Wonder on 21 Mar 2022
Mum’s fear as promising cancer drug out of reach
21 March 2022 - A terminally ill mum desperate for “more time” with her family was “broken” when she learnt the ...
Posted by Michael Wonder on 20 Mar 2022
ProCare supports PHARMAC’s proposal to widen access to the flu vaccine
18 March 2022 - Leading health care provider ProCare has today made a submission in support of PHARMAC’s proposal to ...
Posted by Michael Wonder on 20 Mar 2022
Critics say Australia's private health insurance system is broken. Here's what they say we can do to fix it
20 March 2022 - It's a question many Australians are asking when confronted with their private health insurance payments these ...
Posted by Michael Wonder on 20 Mar 2022
AbbVie expands immunology portfolio in Canada as Health Canada approves Skyrizi (risankizumab) for the treatment of adults with active psoriatic arthritis
17 March 2022 - Approval supported by data from two Phase 3 studies evaluating Skyrizi in psoriatic arthritis patients, KEEPsAKE-1 ...
Posted by Michael Wonder on 20 Mar 2022
NHS fast tracks new ‘gamechanging’ drug for lung cancer
18 March 2022 - A targeted new drug for a rare and aggressive form of lung cancer will be fast-tracked ...
Posted by Michael Wonder on 20 Mar 2022
U.S. Food and Drug Administration approves first LAG-3 blocking antibody combination, Opdualag (nivolumab and relatlimab-rmbw), as treatment for patients with unresectable or metastatic melanoma
18 March 2022 - Opdualag is a first in class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and ...
Posted by Michael Wonder on 19 Mar 2022
COVID-19: a second booster reserved for those most at risk
18 March 2022 - While the COVID-19 epidemic seems to be on the rise again after a few weeks of decline, ...
Posted by Michael Wonder on 19 Mar 2022
Final reconciliation of savings from side agreements for the full year 2021
18 March 2022 - TLV has presented the final reconciliation to the government of the outcome of the rebates in ...
Posted by Michael Wonder on 19 Mar 2022
Medical devices savings ‘missed’
17 March 2022 - Private health insurers say consumers will miss out on big savings on their premiums because the ...
Posted by Michael Wonder on 19 Mar 2022
Heron Therapeutics announces approval of Zynrelef by Health Canada for the management of post-operative pain
17 March 2022 - ZYNRELEF is the first and only extended-release local anaesthetic approved by Health Canada. ...
Posted by Michael Wonder on 18 Mar 2022
Advocates say PHARMAC too slow on drugs to help treat COVID-19
19 March 2022 - Kiwis have been left waiting for a new antiviral drug to treat COVID-19 because PHARMAC was too ...